PD-1/PD-L1抑制剂联合抗血管内皮生长因子药物免疫治疗晚期肝癌的研究进展  

Research progress on combined immunotherapy with PD-1/PD-L1 inhibitors and anti-VEGF agents in advanced hepatocellular carcinoma

作　　者：黄燕妮 蓝雪灵 朱敏敏 韦锦斌[1,2] 李艳 董敏[1,2] HUANG Yan-ni;LAN Xue-ling;ZHU Min-min;WEI Jin-bin;LI Yan;DONG Min(School of Pharmacy,Guangxi Medical University;Engineering Research Center for Precision Development and High-value-tilization of Marine Biological Medicine in Beibu Gulf of Guangxi Zhuang Autonomous Region;Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学药学院 [2]广西壮族自治区北部湾海洋生物医药精准开发和高值利用工程研究中心 [3]广西医科大学附属肿瘤医院,广西南宁530021

出　　处：《中国药理学通报》2024年第8期1429-1436,共8页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金青年基金资助项目(No.81302859);广西自然科学基金面上项目(No.2021GXNSFAA196070,2018GXNSFAA050121);广西壮族自治区大学生创新创业训练项目(No.202110598158,202110598117)。

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)是全球高发的恶性肿瘤。程序性死亡蛋白-1(programmed death protein-1,PD-1)/程序性死亡蛋白配体-1(programmed death protein ligand-1,PD-L1)抑制剂可通过阻断T细胞负调节信号,抑制肿瘤细胞免疫逃逸途径,重新激活抗肿瘤免疫应答过程,成为晚期HCC治疗的新手段。然而,长期临床结果显示,采用PD-1/PD-L1抑制剂单药治疗晚期HCC的病人仍存在较高的复发率和转移率。免疫联合疗法是目前针对晚期HCC患者的新的治疗策略,其中PD-1/PD-L1抑制剂联合抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物在晚期HCC治疗中显示出了良好的疗效和安全性。PD-1/PD-L1抑制剂联合抗VEGF药物可通过参与癌症免疫循环途径抑制肝癌细胞的生长。该文就PD-1/PD-L1抑制剂联合抗VEGF药物在晚期HCC治疗中的临床研究作一综述。Hepatocellular carcinoma(HCC)is one of the most common malignant tumors globally.Programmed death protein-1(PD-1)/programmed death protein ligand-1(PD-L1)inhibitors promote the reactivation of anti-tumor immune response by blocking the negative modulatory signaling pathway of T cells'activation and inhibiting the immune escape pathway of tumor cells.PD-1/PD-L1 inhibitors become a novel therapeutic strategy to treat HCC.However,long-term clinical outcomes show that HCC patients treated with anti-PD-1/PD-L1 monotherapy still have high rates of recurrence and metastasis.Combination immunotherapy is a novel therapeutic strategy to treat advanced HCC patients,among which PD-1/PD-L1 inhibitors in combination with anti-vascular endothelial growth factor(VEGF)agents have showed promising efficacy and better safety.PD-1/PD-L1 inhibitors plus anti-VEGF agents combined therapy inhibit the growth of hepatoma cells by participating in the cancer immunity cycle pathway.This review focuses on the research progress of PD-1/PD-L1 inhibitors,anti-VEGF agents and their combined therapy in the clinical treatment of HCC.

关 键 词：PD-1/PD-L1抑制剂 抗VEGF药物 免疫联合疗法 肝细胞癌 抗血管生成 癌症免疫循环 

分 类 号：R392.11[医药卫生—免疫学] R453[医药卫生—基础医学] R735.7R977.6